NASDAQ:QNTM Stock Quote

Quantum BioPharma (NASDAQ: QNTM) reported its financial results for the fourth quarter and year ended Dec. 31, 2024, highlighting a strengthened balance sheet and strategic advances across its clinical programs. The company removed its Material Uncertainty Related to Going Concern, with $12.1 million in cash and a 36% reduction in net cash used for operations year over year. Operating expenses dropped over 32% to $16.1 million, while net loss narrowed 18% to $14.9 million. Quantum completed a clinical trial for its unbuzzd alcohol detox supplement, which showed a 40% faster reduction in blood alcohol concentration among participants. unbuzzd is now expanding through a master distribution agreement across Latin America and ongoing U.S. sales. The company also completed a Phase 1 trial of its multiple sclerosis treatment Lucid-MS, which was deemed safe and well-tolerated, with Phase 2 preparations underway. Other initiatives included a dual listing on Upstream, crypto treasury diversification, and the early development of rekvry, an alcohol misuse treatment for emergency settings.

Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets

Completion of unbuzzd™ Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company’s Pipeline of Products and Assets

Quantum BioPharma Ltd. Dual Lists on Upstream's Global Securities Trading App

Trading to become available January 14th under 'QNTM'

Quantum BioPharma (NASDAQ: QNTM) has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will remain as an advisor. Lynch, a prominent advocate against micro-cap stock manipulation and CEO of Power Nickel (TSXV: PNPN), brings deep experience in biotech, mining finance and market reform. He is also a co-founder of Cardiol Therapeutics (NASDAQ: CRDL) and a consultant to bionxt solutions. As part of the appointment, Quantum granted Lynch 50,000 stock options at C$9.90 per share, expiring March 26, 2027.

TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company.

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition Corporation has introduced a new format of its unbuzzd beverage supplement—“On-the-Go Powder Stick Packs”—now sold in 8-pack display boxes. Designed for convenience and portability, the new packaging supports broader retail distribution in convenience, liquor, and drug stores across the United States. The product, which accelerates alcohol metabolism and reduces hangover symptoms, is also available online in 3-pack, 8-pack, and 18-pack formats. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives up to 7% in royalties on sales of unbuzzd . The company also renewed a 45-day market awareness campaign with Life Water Media beginning March 26.

New Ultra-Portable unbuzzd™ Single-Use Powder Sticks in Convenient 8-Pack Display Boxes Now Available for US Retailers

TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,500,000 worth of Bitcoin (BTC) and other cryptocurrencies, growing and increasing its crypto assets as part of its strategic efforts. This brings the total amount of Bitcoin (BTC), and other cryptocurrencies purchased to USD $3,500,000. As previously announced, the company will continue to allow for future financings and other transactions to be carried out in cryptocurrency.

Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of its Phase 1 clinical trial evaluating Lucid-21-302 (“Lucid-MS”), a first-in-class neuroprotective compound for multiple sclerosis. A final safety review committee meeting confirmed that Lucid-MS was well-tolerated with no serious adverse events. The drug, designed to stabilize the myelin sheath and protect against demyelination, showed promising safety results, paving the way for a Phase 2 trial in MS patients. Company executives emphasized the milestone as a key step toward drug approval and commercialization.

Safety Review Committee Found No Safety Concerns Following Milestone Trial

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (“BTC”) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $2,000,000. As previously announced, the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.

Quantum BioPharma (NASDAQ: QNTM) has retained MZHCI, an MZ Group company, to lead its investor relations and financial communications efforts. The initiative aims to enhance the company’s visibility within the investment community, emphasizing its portfolio focused on brain disorders and alcohol health. MZ will highlight Quantum BioPharma’s products, including unbuzzd and rekvry, which address excessive alcohol use, and its research into demyelinating diseases such as multiple sclerosis. Chris Tyson, executive vice president at MZ North America, noted the significant market potential for these innovations.

TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of MZHCI, LLC, an MZ Group Company (“MZ”), to lead a comprehensive strategic investor relations and financial communications program across all key markets.

Quantum BioPharma (NASDAQ: QNTM) has retained Enterprise Canada Inc. and Empire Market Ventures, LLC to lead its public relations and investor awareness efforts. Enterprise, engaged indefinitely, will develop the company’s media strategy, while Empire, engaged for three months starting Feb. 7, 2025, will focus on investor marketing and outreach. The company highlighted progress on its key products, including unbuzzd, a rapid alcohol detoxification beverage set for Q1 2025 availability, rekvry , an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment moving toward Phase 2 trials.

TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of Enterprise Canada Inc. (“Enterprise”) and Empire Market Ventures, LLC (“Empire”) (together, the “Agencies”) to lead its comprehensive public relations and investor awareness programs, respectively, across all key markets.

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Celly Nutrition Corp., has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering on a major U.S. exchange. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives a 7% royalty on sales of its product, unbuzzd, until payments total $250 million, after which royalties drop to 3% in perpetuity. Celly Nutrition signed a Letter of Engagement on Feb. 4, 2025, for advisory services related to a potential uplisting, reverse merger, or IPO. CEO John Duffy emphasized the capital raise will support marketing and distribution expansion for unbuzzd, while Board Co-Chair Gerry David highlighted strong investor interest in the brand.

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that its licensee Celly Nutrition Corporation, the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms –announced that it has engaged a leading New York Investment Bank to raise up to $10 million USD in capital and explore an initial public offering on a major US public exchange, subject to requisite regulatory approval.

Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzd, significantly accelerates alcohol metabolism and reduces symptoms of intoxication and hangovers. The double-blind, placebo-controlled study showed that unbuzzd lowered blood alcohol concentration by over 40% faster within 30 minutes compared to placebo, while improving alertness and stabilizing heart rate and blood pressure. Participants also reported reduced mental fatigue and hangover symptoms without adverse side effects. Quantum BioPharma CEO Zeeshan Saeed highlighted unbuzzd as a breakthrough in promoting safe and responsible alcohol consumption.

Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd(TM), a novel alcohol detoxification beverage. Through strategic investments and a focused R&D model, Quantum BioPharma seeks to deliver meaningful health improvements while maximizing shareholder value.

Awards in favour of Quantum BioPharma Total Approximately $3 Million

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased USD $1,000,000 Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. As well, going forward the Company will allow for future financing and other transactions to be carried out in cryptocurrency.

TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that the safety review committee recommends commencing dosing of the second cohort in its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." The safety review committee made this recommendation after reviewing safety and pharmacokinetic data from participants in the first cohort.